Prevalence of autism and parentally reported triggers in a north east London population

R Lingam, A Simmons, N Andrews, E Miller, J Stowe, B Taylor

Background: The recorded prevalence of autistic spectrum disorders has risen over recent decades. Measles, mumps and rubella (MMR) vaccine has been blamed, by causing a “new variant” form of “regressive autism” associated with “autistic enterocolitis”.

Aims: To estimate the prevalence of autism and to assess any changes in parental perception regarding the onset or causes of autism.

Methods and Results: A total of 567 children with autistic spectrum disorder in five districts in north east London were identified, born 1979–98. Reported autism, excluding the 94 cases of Asperger’s syndrome, increased by year of birth until 1992, since when prevalence has plateaued. This flattening off persisted after allowing for expected delay in diagnosis in more recent birth cohorts. The age at diagnosis of autistic spectrum disorder was estimated to have decreased per five year period since 1983, by 8.7% for childhood autism and by 11.0% for atypical autism. There was some evidence that MMR was more likely to be mentioned as a trigger after August 1997 than before.

Conclusions: The prevalence of autism, which was apparently rising from 1979 to 1992, reached a plateau from 1992 to 1996 at a rate of some 2.6 per 1000 live births. This levelling off, together with the reducing age at diagnosis, suggests that the earlier recorded rise in prevalence was not a real increase but was likely due to factors such as increased recognition, a greater willingness on the part of educationalists and families to accept the diagnostic label, and better recording systems. The proportion of parents attributing their child’s autism to MMR appears to have increased since August 1997.

Case identification and ascertainment

Records were identified during the year 2000 for all children in the study districts with a diagnosis of autistic spectrum disorder (ASD) born since 1979. An initial list of children was compiled from computer based disability registers (RICHS, or TotalCare). Relevant ICD-9 and ICD-10 codes were identified. This computer generated list was augmented by approaching consultant community paediatricians, special needs schools, and local child psychiatry teams for any additional cases. Some 90% of cases (range 88–96% for the five districts) were obtained from the computerised disability register (special needs module).

The diagnosis accepted was that of the principal clinician who had seen the child. Diagnostic validity was checked by matching symptoms recorded in the notes against ICD-10 criteria. Each record (usually comprising hospital, child development team, school, and health visitor notes) was systematically reviewed by one of two paediatric registrars. There was no direct patient, general practitioner, or other clinician contact.

METHODS

Five of the eight districts from the original survey were included. Three were country town/semi-rural districts, one was suburban, and the other inner-city. The other three districts (two country town/semi-rural, one suburban) had undergone changes in personnel, management arrangements, and/or computer systems, which made them unsuitable for repeat study. The original eight districts were chosen for study as users of the Regional Interactive Child Health computing System (RICHS) special needs module. The remaining eight RICHS users in North East Thames did not use this module. The original eight districts and the five of those eight used for the present study provide a general population sample with a broad range of social and cultural characteristics.

Abbreviations: ASD, autistic spectrum disorder; MMR, measles, mumps, and rubella
Table 1 Description of the 567 children with autistic spectrum disorders

<table>
<thead>
<tr>
<th>Variable</th>
<th>Childhood (n=278)</th>
<th>Atypical (n=195)</th>
<th>Asperger’s (n=94)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number overall [prevalence per 10000]*</td>
<td>278 (14.9)</td>
<td>195 (10.5)</td>
<td>94 (5.0)</td>
</tr>
<tr>
<td>Number male [%]</td>
<td>230 (83%)</td>
<td>158 (81%)</td>
<td>81 (86%)</td>
</tr>
<tr>
<td>Number with regression [%]†</td>
<td>75 (27%)</td>
<td>43 (23%)</td>
<td>2 (2%)</td>
</tr>
<tr>
<td>Number with bowel symptoms [%]</td>
<td>49 (18%)</td>
<td>32 (16%)</td>
<td>9 (10%)</td>
</tr>
<tr>
<td>Median age in months at regression (IQR)</td>
<td>18 (14–20)</td>
<td>20 (18–26)</td>
<td>40 (2 cases, at 15, 65)</td>
</tr>
<tr>
<td>Numbers</td>
<td>74</td>
<td>43</td>
<td>2</td>
</tr>
<tr>
<td>Median age in months at parental concern (IQR)</td>
<td>18 (14–22)</td>
<td>22 (16–30)</td>
<td>28 (20–42)</td>
</tr>
<tr>
<td>Numbers</td>
<td>262</td>
<td>179</td>
<td>85</td>
</tr>
<tr>
<td>Median age in months at provisional diagnosis (IQR)</td>
<td>35 (30–41)</td>
<td>44 (34–64)</td>
<td>74 (56–115)</td>
</tr>
<tr>
<td>Numbers</td>
<td>273</td>
<td>191</td>
<td>87</td>
</tr>
<tr>
<td>Median age in months at final diagnosis (IQR)</td>
<td>40 (34–48)</td>
<td>51 (40–78)</td>
<td>97 (70–125)</td>
</tr>
<tr>
<td>Numbers</td>
<td>266</td>
<td>171</td>
<td>89</td>
</tr>
</tbody>
</table>

*Prevalence was calculated using the subset of 429 children aged 5–14 at the end of 2000 and using 1996 mid-census denominator data for 5–14 year olds in the study area (186206).
†Regression status not available for four atypical cases and two Asperger’s cases.
IQR, interquartile range.

Information recorded

The dates of provisional diagnosis, definitive diagnosis, age at first parental concern about the child’s development, and age at developmental regression where a feature, were noted. Provisional diagnosis was defined as the first mention of the terms “autism” or “autistic spectrum” in any clinical record or letter. Definitive diagnosis was defined as when the principal clinician documented autism or Asperger’s syndrome as a diagnosis.

Regression reflected mention in the notes of the word or a description of a loss of skills, even if transitory. Additional information was extracted from the case notes of children with possible regression to determine which skills were lost, at what age this had occurred, and possible triggers identified by the family, as well as when regression was first documented in the clinical notes and whether there had been any change in the history of regression.

General health concerns, including bowel problems persisting at least three months, were recorded. It is likely that any significant health problem would be documented as children with ASDs are often seen many times for diagnosis and then have regular review, usually at least annually.

Immunisation details were obtained from the local child health computer system (RICHS or TotalCare). This information was recorded independently of the clinical record; researchers assessing the clinical records were blind as to the vaccination dates.

To ensure consistency of data collection between researchers, 40 cases were assessed independently by both recorders or an independent observer; when the data recorded were compared on key variables, including age at first parental concern, age at regression, and age at provisional and final diagnosis, over 98% showed an exact match. Computerised data were double entered and validated, then anonymised. Ethical approval for the study was obtained from the relevant committees.

Analysis

Modelling of trends in autism by year of birth and age at diagnosis

These analyses used data from all cases of childhood and atypical autism, born between 1983 and 1999, who had a provisional diagnosis by the age of 10 years and before the end of December 1999. These restrictions reflected the likely underascertainment of cases born prior to 1983 and of cases diagnosed in the year 2000, as well as the large potential effect of a few outliers diagnosed after the age of 10 years. Recorded age at provisional diagnosis was used in these analyses to provide the earliest age at which cases were identified as autism.

In order to obtain estimates of expected total cases (that is, including those not yet diagnosed for more recent years) the data were cross-classified by year of birth and age in years at diagnosis and analysed using Poisson regression with Excel and S-plus. The estimated number of cases in each cell (e) was modelled by a function of the form $e(t,s) = \lambda(t)f(s|t)$, where $\lambda(t)$ represents the estimated number of births in year $t$ diagnosed as autism and $f(s|t)$ is the probability that a case has a provisional diagnosis at age $s$ given that the case was born in year $t$. The age distribution was modelled using a gamma distribution with mean $\mu = \exp(-pt)$ where $p$ is the parameter which allows for an exponential change in the mean age at provisional diagnosis. The gamma distribution was then truncated to restrict age at diagnosis to be between 1 and 10 years. The gamma distribution was chosen because it provided a good fit to the positively skewed distribution of age at diagnosis. The function $\lambda(t)$ was modelled using linear, quadratic, and cubic polynomials. The linear model fits an exponential increase over time with $\lambda(t) = \exp(b_0 + b_1t)$, the quadratic model with $\lambda(t) = \exp(b_0 + b_1t + b_2t^2)$ allows for a departure from an exponential increase, such as a flattening off and decline, the cubic model with $\lambda(t) = \exp(b_0 + b_1t + b_2t^2 + b_3t^3)$ allows for a further change such as a decline, then a rise, then a decline.

Separate models as appropriate for the data, were fitted for the childhood and atypical cases and expected numbers by birth year were calculated allowing for the estimated number of cases yet to be diagnosed. The overall expected numbers were then calculated by adding up the expected numbers of childhood and atypical cases.

**RESULTS**

**Descriptive**

Table 1 shows details of the study population. A total of 567 children with ASD were identified, born between 1979 and 1998. Of these, 278 (49%) had childhood autism, 195 (34%) atypical autism, and 94 (17%) Asperger’s syndrome.

A diagnosis of childhood autism could be ICD-10 confirmed from symptoms detailed in the clinical notes in 248 of 278 children (89%). For the other 30 there was insufficient information recorded, especially regarding social interaction; 17 of these cases had less than two social interaction symptoms documented. Four others presented after 3 years of age with...
no symptoms recorded in the notes regarding their condition before the third birthday.

All but one child with atypical autism met the criteria for diagnosis, and 79 (84%) of the 94 children with Asperger's syndrome met either ICD-10 or Gilberg and Gilberg's 1989 criteria. The proportion of cases with the different types of autism was similar across the five study districts (p = 0.32).

Overall 83% of the cases were male, with no significant difference in this percentage by type of autism (p = 0.56). This sex difference is comparable with other published data. Some 188 children were documented as attending a special school; 180 were at a special unit and 140 were integrated into mainstream education. The remaining 59 children were pre-school, had left school, or no school was mentioned in the notes. The percentage of children who were documented as having seen different health professionals varied: 466 of 473 (99%) of children with childhood or atypical autism were documented as having seen a developmental paediatrician, and 460 (97%) a speech and language therapist. Some 436 (92%) were recorded as having been seen by an educational psychologist and 200 (42%) had attended a specialist centre for assessment of autism. However, only 18 (6%) childhood cases, eight (4%) atypical cases, and one (1%) child with Asperger's syndrome were documented as having seen a specialist gastroenterologist. Bowel problems were reported in 17% of cases overall, with no significant difference by type of autism (p = 0.18). A detailed description of the bowel problems in this study population and the lack of a relation with MMR vaccination have been reported elsewhere.

Using denominator data for children aged 5–14 in the five districts, prevalence rates were calculated for those cases aged 5–14 at the end of 2000 (table 1). These rates give an overall estimate for the prevalence of atypical and childhood autism of 19.3 per 10 000 children.

Median age at regression, parental concern, and provisional and final diagnosis were much higher in cases of Asperger's syndrome and slightly higher in those with atypical compared with childhood autism (table 1). Regression was reported in only two cases with Asperger's syndrome (2%), compared to 23% with atypical autism and 27% with childhood autism. Because of these, and other differences from childhood and atypical autism, Asperger cases were not included in subsequent analyses. There were some missing data regarding age at regression, first parental concern, and provisional and final diagnosis for all forms of autism. This reflected the difficulties of assigning accurate dates from sometimes limited clinical records. The missing data are unlikely to have had any effect on the number of cases of childhood and atypical autism identified before 2000 as we identified cases until the end of 2000 and the median gap between provisional and final diagnosis for childhood and atypical autism was about six months, and less in recent years.

The median age at provisional and final diagnosis was more than 15 months after first parental concern or regression onset. There was a tendency to preferential reporting to the nearest 6 months, at 12, 18, 24, 30, and 36 months. The median ages at provisional and final diagnosis are likely to underestimate the true average age at diagnosis because children born in recent years could only be included if they were diagnosed in young. However, the modelling of trends in autism by year of birth and age at diagnosis allowed corrected estimates of age at diagnosis (see below).

Regression
Regression was reported in 118 cases (25%) with atypical and childhood autism. The age when regression began was reported skill losses with the regression included: 59 (56%) regression or loss of speech as the only symptom; eight (8%) behaviour alone; 32 (30%) both behaviour and language; and two (2%) motor regression. The type of regression was not specified for the other five children.

In 44 (42%) of the 106 children with detailed information on regression, a specific trigger was mentioned as a possible cause. The most common (13 children) was a household or social change such as the birth of a sibling, then vaccination (12 cases). Other triggers mentioned were: viral and bacterial infections (n = 7), seizures (n = 7), postsurgery (n = 2), and other causes (n = 3). The MMR vaccine was mentioned specifically in eight of the 12 cases where a vaccine was suspected. Although families would not have been directly asked about this possibility, this finding suggests that very few parents (less than 2% in this cohort) considered that MMR vaccine might have triggered their child's autism.

Widespread public concern about the possible relation between autism and MMR began in August 1997, with the pre-publication release of information about the Wakefield study, which attracted considerable and ongoing media attention. The date at which onset of developmental regression was first recorded in the notes was obtained for the 106 cases. After excluding unvaccinated cases and those vaccinated when aged over 24 months (of whom all but one were children vaccinated in the 1988–89 catch-up campaign), we found MMR was reported as the trigger in 6/30 (20.0%) post-August 1997 compared to 2/46 (4.3%) before August 1997 (p = 0.052).

From August 1997 the reported presence or timing of regression changed in 13 cases. For six of these, regression was mentioned for the first time after August 1997, even though many health professionals had seen these children before this date. In seven cases the recorded timing of onset of regression changed in relation to MMR: six closer, one further away.

Modelling of trends in autism by year of birth and age at diagnosis
Figure 1 shows the observed and expected number of cases by year of birth for childhood and atypical autism combined. This clearly illustrates that the recorded rise in cases by year of birth which occurred in children with autism born up to 1992 did not continue beyond that year. Figure 2 shows the separate data for childhood and atypical autism. The levelling after 1991 (with = 50 new cases total per year) gives a prevalence of autism since then, for children age 5–14 years in this population, of some 2.6/1000 live births (childhood 1.5; atypical 1.1), using as the denominator Office of National Statistics mid-year population estimates. Confirming our previous finding there was no evidence of a step up in prevalence in the cohorts eligible to receive MMR vaccine in the second year of childhood. Only one child regressed after 50 months—at 88 months. Reported skill losses with the regression included: 59 (56%) regression or loss of speech as the only symptom; eight (8%) behaviour alone; 32 (30%) both behaviour and language; and two (2%) motor regression. The type of regression was not specified for the other five children.
better record systems.

accept the diagnostic label, greater awareness of autism by
in part, a greater willingness by educationalists and parents to
practice has changed. Such change is likely to reflect, at least
diagnosis has decreased over time. This suggests that diagnostic
1992 to 1996 were steady at about 45–50 cases per birth year
stopped and that prevalence has reached a plateau. Prevalence
years data in the present study suggests that the rise has
reported cases by year of birth.

For atypical autism, the best fitting model for the trend by
birth year was a quadratic polynomial, which is due to the fact
that the exponential apparent increase stopped after 1990.
There was evidence of a reduction in the mean age at diagno-
sis over time, with an average 8.7% decrease every five years
(p = 0.021). The overall average age at provisional diagnosis
was 3.2 years. However, the average age was estimated to have
reduced from 3.5 years in 1985 to 3.0 by 1995.

For atypical autism the best fitting model for the trend over
time was a cubic polynomial, which is due to an initial appar-
ent low prevalence, followed by an increase, then a levelling off
and slight decrease. There was evidence of a reduction in the
mean age at diagnosis over time, with an average 11.0% decrease
every five years (p = 0.04). The overall average age at provisional
diagnosis for atypical autism was 5.2 years; however, the average age was estimated to have fallen from 6.0 in 1985 to 4.9 by 1995.

DISCUSSION
We have shown a levelling off since the early 1990s in the previ-
ously rising recorded prevalence of autism. In our earlier
study we showed an exponential increase in the number of
reported cases by year of birth.1 The additional two and a half
years data in the present study suggests that the rise has
stopped and that prevalence has reached a plateau. Prevalence
estimates for combined childhood and atypical autism from
1992 to 1996 were steady at about 45–50 cases per birth year
in this study population. We have also shown that age at diag-
nosis has decreased over time. This suggests that diagnostic
practice has changed. Such change is likely to reflect, at least
in part, a greater willingness by educationalists and parents to
accept the diagnostic label, greater awareness of autism by
health professionals, especially the considerable recent expan-
sion of specialist paediatricians trained to recognise the
conditions, changes in diagnostic criteria for autism, as well as
better record systems.

We have also documented changes in the likelihood that
parents would incriminate MMR as the trigger for their child's
autistic state, particularly for any associated regression, since
1997, the year when publicity about a possible link between
MMR vaccination and autism became widespread. In some
cases, we found that the history of regression had changed
since 1997 from that recorded earlier. These findings are
likely to affect systematically the validity of the self control-
ed case series analysis linking vaccination to age at regres-
sion in children with autism. We investigated this
possibility and found such evidence of parental recall bias
when reporting the onset of regression in relation to MMR
vaccination since 1997.12

Our prevalence rate for childhood autism of 14.9 per 10 000
for children age 5–14 years is comparable with the 16.8
reported by Chakrabarti and Fombonne16 for Staffordshire
children. Both figures are rather lower than the 30.8 (which
included some cases of Asperger's syndrome) in south
east England, reported by Baird and colleagues.17 Our rates
(10.5 per 10 000) for atypical autism and (5.0) for Asperger's
syndrome are likely to be an underestimate, as children
with autistic spectrum disorder known to the health services
are likely to be at the more severe end of the spectrum and
more likely to present in the preschool period. It is
likely that some of our atypical cases might actually be child-
hood autism; limitations in the available health records,
especially regarding social interaction, made allocation diffi-
cult in some instances. Clinical notes were not always
complete, but diagnoses could be verified in the majority of
cases. The comparable results for childhood autism between
our study and that in Stafford shows the potential effective-
ness of health service disability registers as an epidemiologi-
ical tool.

Developmental regression in autism is not a new finding.
Lotter in 1966 described developmental setbacks, including
speech loss, in 10 of 32 autistic children.18 Fombonne and
Chakrabarti19 document reported rates of regression varying
between 22% and 50%, in earlier published studies, with no
evidence of a rising proportion in more recent case series. The
proportion of children with autism who have regression is
unclear.4 Children with autism often fail to develop normal
social speech between the age of 12 and 18 months. Parents
and even health workers may over-interpret as regression, the
loss of infantile babbling which occurs in normal children as
well as in children with autism during the same age span. True regression may occur in rather less than 20% of
cases.19

In our study, a sizable minority of parents had an explana-
tion for their child's "regressive loss of skills". Whether, as
stated in many cases, these children were completely "normal" before the "regression", or were in fact subtly
different, is a matter of conjecture. We found that the trigger
for regression in some cases had changed after the publicity
and media attention associated with, and preceding,1 the 1998
Wakefield et al paper.2 Before August 1997, parents incrimi-
nated trigger factors such as domestic stress, seizures, or viral
illness. Post-1997, parents were more likely to attribute
regression to vaccination, especially the MMR vaccine. Parents
are usually very reliable historians regarding their child's early
life. Sometimes, however, there is the possibility of recall bias,
in some instances reflecting changing beliefs about causal
relationships. An expert group convened by the Medicines
Control Agency reviewed the records of 92 children with
autism whose parents thought that MMR had caused or trig-
ger their child's condition. In 36 (39%) there was evidence
in the medical record that there had been concerns about the
child's behaviour before the MMR vaccination. However, in
only one (1%) of these cases did the parent recall this early
concern.20

Davidovitch et al examined paternal perceptions in
autism.21 They found that where children with autism had
developmental regression, almost all mothers attributed
specific causes for their child's autism, compared to only two
thirds of mothers where children did not show regression.
They stated: “it is possible that regression is associated with a different perception of the condition by parents”.

Our large population study, using robust methodology and analytical methods, has helped define the current epidemiology of the condition, confirming and extending earlier findings. The prevalence of autism appears to have stabilised. There is no evidence for a new phenotype of autism (“new variant”, or “regressive autism”).

45 The claims that MMR vaccine is involved in the initiation of autism, and/or with regression, and/or with bowel problems associated with autism, are not supported by any credible scientific evidence, while there is compelling and increasing evidence showing no association. Further research is needed into the causes and best treatment of autism and related conditions. Our finding of changing histories with recall bias, will affect the interpretation of future epidemiological research in autism.

ACKNOWLEDGEMENTS
This study was funded by a grant from the Department of Health. We are very grateful to the paediatricians, child health computing staff and managers, child psychiatrists, and special school staff who helped with case identification and data.

Authors’ affiliations
R Lingam, A Simmons, J Stowe, B Taylor, Centre for Community Child Health, Royal Free and University College Medical School, Royal Free Campus, University College London, London NW3 2PF
E Miller, Immunisation Division, Communicable Disease Surveillance Centre, Public Health Laboratory Service, 61 Colindale Avenue, London NW9 5EQ
N Andrews, Statistics Unit, Public Health Laboratory Service, 61 Colindale Avenue, London NW9 5EQ

REFERENCES
Prevalence of autism and parentally reported triggers in a north east London population

R Lingam, A Simmons, N Andrews, E Miller, J Stowe and B Taylor

Arch Dis Child 2003 88: 666-670
doi: 10.1136/adc.88.8.666

Updated information and services can be found at:
http://adc.bmj.com/content/88/8/666

These include:

References
This article cites 11 articles, 4 of which you can access for free at:
http://adc.bmj.com/content/88/8/666#BIBL

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Topic Collections
Articles on similar topics can be found in the following collections

- Autism (133)
- Child and adolescent psychiatry (paediatrics) (683)
- Pervasive developmental disorder (138)
- Dentistry and oral medicine (147)

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/